Medical Care
Indolent Lymphoma Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
- Sep 11, 24
- ID: 546867
- Pages: 109
- Figures: 187
- Views: 1
The global market for Indolent Lymphoma Treatment was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Indolent Lymphoma Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Indolent Lymphoma Treatment by region & country, by Type, and by Application.
The Indolent Lymphoma Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Indolent Lymphoma Treatment.
Market Segmentation
By Company
Altor BioScience Corporation
Amgen Inc.
Astellas Pharma Inc.
Bayer AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
Incyte Corporation
Infinity Pharmaceuticals, Inc.
Juno Therapeutics Inc.
MedImmune, LLC
Segment by Type:
BI-836826
ALT-803
BMS-986016
CC-122
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Indolent Lymphoma Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Indolent Lymphoma Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Indolent Lymphoma Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Indolent Lymphoma Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Indolent Lymphoma Treatment by region & country, by Type, and by Application.
The Indolent Lymphoma Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Indolent Lymphoma Treatment.
Market Segmentation
By Company
Altor BioScience Corporation
Amgen Inc.
Astellas Pharma Inc.
Bayer AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
Incyte Corporation
Infinity Pharmaceuticals, Inc.
Juno Therapeutics Inc.
MedImmune, LLC
Segment by Type:
BI-836826
ALT-803
BMS-986016
CC-122
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Indolent Lymphoma Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Indolent Lymphoma Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Indolent Lymphoma Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
1 Market Overview
1.1 Indolent Lymphoma Treatment Product Introduction
1.2 Global Indolent Lymphoma Treatment Market Size Forecast
1.3 Indolent Lymphoma Treatment Market Trends & Drivers
1.3.1 Indolent Lymphoma Treatment Industry Trends
1.3.2 Indolent Lymphoma Treatment Market Drivers & Opportunity
1.3.3 Indolent Lymphoma Treatment Market Challenges
1.3.4 Indolent Lymphoma Treatment Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Indolent Lymphoma Treatment Players Revenue Ranking (2023)
2.2 Global Indolent Lymphoma Treatment Revenue by Company (2019-2024)
2.3 Key Companies Indolent Lymphoma Treatment Manufacturing Base Distribution and Headquarters
2.4 Key Companies Indolent Lymphoma Treatment Product Offered
2.5 Key Companies Time to Begin Mass Production of Indolent Lymphoma Treatment
2.6 Indolent Lymphoma Treatment Market Competitive Analysis
2.6.1 Indolent Lymphoma Treatment Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Indolent Lymphoma Treatment Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Indolent Lymphoma Treatment as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 BI-836826
3.1.2 ALT-803
3.1.3 BMS-986016
3.1.4 CC-122
3.1.5 Others
3.2 Global Indolent Lymphoma Treatment Sales Value by Type
3.2.1 Global Indolent Lymphoma Treatment Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Indolent Lymphoma Treatment Sales Value, by Type (2019-2030)
3.2.3 Global Indolent Lymphoma Treatment Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Clinic
4.1.3 Others
4.2 Global Indolent Lymphoma Treatment Sales Value by Application
4.2.1 Global Indolent Lymphoma Treatment Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Indolent Lymphoma Treatment Sales Value, by Application (2019-2030)
4.2.3 Global Indolent Lymphoma Treatment Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Indolent Lymphoma Treatment Sales Value by Region
5.1.1 Global Indolent Lymphoma Treatment Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Indolent Lymphoma Treatment Sales Value by Region (2019-2024)
5.1.3 Global Indolent Lymphoma Treatment Sales Value by Region (2025-2030)
5.1.4 Global Indolent Lymphoma Treatment Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Indolent Lymphoma Treatment Sales Value, 2019-2030
5.2.2 North America Indolent Lymphoma Treatment Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Indolent Lymphoma Treatment Sales Value, 2019-2030
5.3.2 Europe Indolent Lymphoma Treatment Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Indolent Lymphoma Treatment Sales Value, 2019-2030
5.4.2 Asia Pacific Indolent Lymphoma Treatment Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Indolent Lymphoma Treatment Sales Value, 2019-2030
5.5.2 South America Indolent Lymphoma Treatment Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Indolent Lymphoma Treatment Sales Value, 2019-2030
5.6.2 Middle East & Africa Indolent Lymphoma Treatment Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Indolent Lymphoma Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Indolent Lymphoma Treatment Sales Value
6.3 United States
6.3.1 United States Indolent Lymphoma Treatment Sales Value, 2019-2030
6.3.2 United States Indolent Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Indolent Lymphoma Treatment Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Indolent Lymphoma Treatment Sales Value, 2019-2030
6.4.2 Europe Indolent Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Indolent Lymphoma Treatment Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Indolent Lymphoma Treatment Sales Value, 2019-2030
6.5.2 China Indolent Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
6.5.3 China Indolent Lymphoma Treatment Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Indolent Lymphoma Treatment Sales Value, 2019-2030
6.6.2 Japan Indolent Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Indolent Lymphoma Treatment Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Indolent Lymphoma Treatment Sales Value, 2019-2030
6.7.2 South Korea Indolent Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Indolent Lymphoma Treatment Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Indolent Lymphoma Treatment Sales Value, 2019-2030
6.8.2 Southeast Asia Indolent Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Indolent Lymphoma Treatment Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Indolent Lymphoma Treatment Sales Value, 2019-2030
6.9.2 India Indolent Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
6.9.3 India Indolent Lymphoma Treatment Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Altor BioScience Corporation
7.1.1 Altor BioScience Corporation Profile
7.1.2 Altor BioScience Corporation Main Business
7.1.3 Altor BioScience Corporation Indolent Lymphoma Treatment Products, Services and Solutions
7.1.4 Altor BioScience Corporation Indolent Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.1.5 Altor BioScience Corporation Recent Developments
7.2 Amgen Inc.
7.2.1 Amgen Inc. Profile
7.2.2 Amgen Inc. Main Business
7.2.3 Amgen Inc. Indolent Lymphoma Treatment Products, Services and Solutions
7.2.4 Amgen Inc. Indolent Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.2.5 Amgen Inc. Recent Developments
7.3 Astellas Pharma Inc.
7.3.1 Astellas Pharma Inc. Profile
7.3.2 Astellas Pharma Inc. Main Business
7.3.3 Astellas Pharma Inc. Indolent Lymphoma Treatment Products, Services and Solutions
7.3.4 Astellas Pharma Inc. Indolent Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.3.5 Bayer AG Recent Developments
7.4 Bayer AG
7.4.1 Bayer AG Profile
7.4.2 Bayer AG Main Business
7.4.3 Bayer AG Indolent Lymphoma Treatment Products, Services and Solutions
7.4.4 Bayer AG Indolent Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.4.5 Bayer AG Recent Developments
7.5 Boehringer Ingelheim GmbH
7.5.1 Boehringer Ingelheim GmbH Profile
7.5.2 Boehringer Ingelheim GmbH Main Business
7.5.3 Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Products, Services and Solutions
7.5.4 Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.5.5 Boehringer Ingelheim GmbH Recent Developments
7.6 Bristol-Myers Squibb Company
7.6.1 Bristol-Myers Squibb Company Profile
7.6.2 Bristol-Myers Squibb Company Main Business
7.6.3 Bristol-Myers Squibb Company Indolent Lymphoma Treatment Products, Services and Solutions
7.6.4 Bristol-Myers Squibb Company Indolent Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.6.5 Bristol-Myers Squibb Company Recent Developments
7.7 Celgene Corporation
7.7.1 Celgene Corporation Profile
7.7.2 Celgene Corporation Main Business
7.7.3 Celgene Corporation Indolent Lymphoma Treatment Products, Services and Solutions
7.7.4 Celgene Corporation Indolent Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.7.5 Celgene Corporation Recent Developments
7.8 Eli Lilly and Company
7.8.1 Eli Lilly and Company Profile
7.8.2 Eli Lilly and Company Main Business
7.8.3 Eli Lilly and Company Indolent Lymphoma Treatment Products, Services and Solutions
7.8.4 Eli Lilly and Company Indolent Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.8.5 Eli Lilly and Company Recent Developments
7.9 F. Hoffmann-La Roche Ltd.
7.9.1 F. Hoffmann-La Roche Ltd. Profile
7.9.2 F. Hoffmann-La Roche Ltd. Main Business
7.9.3 F. Hoffmann-La Roche Ltd. Indolent Lymphoma Treatment Products, Services and Solutions
7.9.4 F. Hoffmann-La Roche Ltd. Indolent Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.9.5 F. Hoffmann-La Roche Ltd. Recent Developments
7.10 Gilead Sciences, Inc.
7.10.1 Gilead Sciences, Inc. Profile
7.10.2 Gilead Sciences, Inc. Main Business
7.10.3 Gilead Sciences, Inc. Indolent Lymphoma Treatment Products, Services and Solutions
7.10.4 Gilead Sciences, Inc. Indolent Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.10.5 Gilead Sciences, Inc. Recent Developments
7.11 Incyte Corporation
7.11.1 Incyte Corporation Profile
7.11.2 Incyte Corporation Main Business
7.11.3 Incyte Corporation Indolent Lymphoma Treatment Products, Services and Solutions
7.11.4 Incyte Corporation Indolent Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.11.5 Incyte Corporation Recent Developments
7.12 Infinity Pharmaceuticals, Inc.
7.12.1 Infinity Pharmaceuticals, Inc. Profile
7.12.2 Infinity Pharmaceuticals, Inc. Main Business
7.12.3 Infinity Pharmaceuticals, Inc. Indolent Lymphoma Treatment Products, Services and Solutions
7.12.4 Infinity Pharmaceuticals, Inc. Indolent Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.12.5 Infinity Pharmaceuticals, Inc. Recent Developments
7.13 Juno Therapeutics Inc.
7.13.1 Juno Therapeutics Inc. Profile
7.13.2 Juno Therapeutics Inc. Main Business
7.13.3 Juno Therapeutics Inc. Indolent Lymphoma Treatment Products, Services and Solutions
7.13.4 Juno Therapeutics Inc. Indolent Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.13.5 Juno Therapeutics Inc. Recent Developments
7.14 MedImmune, LLC
7.14.1 MedImmune, LLC Profile
7.14.2 MedImmune, LLC Main Business
7.14.3 MedImmune, LLC Indolent Lymphoma Treatment Products, Services and Solutions
7.14.4 MedImmune, LLC Indolent Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.14.5 MedImmune, LLC Recent Developments
8 Industry Chain Analysis
8.1 Indolent Lymphoma Treatment Industrial Chain
8.2 Indolent Lymphoma Treatment Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Indolent Lymphoma Treatment Sales Model
8.5.2 Sales Channel
8.5.3 Indolent Lymphoma Treatment Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
1.1 Indolent Lymphoma Treatment Product Introduction
1.2 Global Indolent Lymphoma Treatment Market Size Forecast
1.3 Indolent Lymphoma Treatment Market Trends & Drivers
1.3.1 Indolent Lymphoma Treatment Industry Trends
1.3.2 Indolent Lymphoma Treatment Market Drivers & Opportunity
1.3.3 Indolent Lymphoma Treatment Market Challenges
1.3.4 Indolent Lymphoma Treatment Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Indolent Lymphoma Treatment Players Revenue Ranking (2023)
2.2 Global Indolent Lymphoma Treatment Revenue by Company (2019-2024)
2.3 Key Companies Indolent Lymphoma Treatment Manufacturing Base Distribution and Headquarters
2.4 Key Companies Indolent Lymphoma Treatment Product Offered
2.5 Key Companies Time to Begin Mass Production of Indolent Lymphoma Treatment
2.6 Indolent Lymphoma Treatment Market Competitive Analysis
2.6.1 Indolent Lymphoma Treatment Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Indolent Lymphoma Treatment Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Indolent Lymphoma Treatment as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 BI-836826
3.1.2 ALT-803
3.1.3 BMS-986016
3.1.4 CC-122
3.1.5 Others
3.2 Global Indolent Lymphoma Treatment Sales Value by Type
3.2.1 Global Indolent Lymphoma Treatment Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Indolent Lymphoma Treatment Sales Value, by Type (2019-2030)
3.2.3 Global Indolent Lymphoma Treatment Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Clinic
4.1.3 Others
4.2 Global Indolent Lymphoma Treatment Sales Value by Application
4.2.1 Global Indolent Lymphoma Treatment Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Indolent Lymphoma Treatment Sales Value, by Application (2019-2030)
4.2.3 Global Indolent Lymphoma Treatment Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Indolent Lymphoma Treatment Sales Value by Region
5.1.1 Global Indolent Lymphoma Treatment Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Indolent Lymphoma Treatment Sales Value by Region (2019-2024)
5.1.3 Global Indolent Lymphoma Treatment Sales Value by Region (2025-2030)
5.1.4 Global Indolent Lymphoma Treatment Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Indolent Lymphoma Treatment Sales Value, 2019-2030
5.2.2 North America Indolent Lymphoma Treatment Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Indolent Lymphoma Treatment Sales Value, 2019-2030
5.3.2 Europe Indolent Lymphoma Treatment Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Indolent Lymphoma Treatment Sales Value, 2019-2030
5.4.2 Asia Pacific Indolent Lymphoma Treatment Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Indolent Lymphoma Treatment Sales Value, 2019-2030
5.5.2 South America Indolent Lymphoma Treatment Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Indolent Lymphoma Treatment Sales Value, 2019-2030
5.6.2 Middle East & Africa Indolent Lymphoma Treatment Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Indolent Lymphoma Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Indolent Lymphoma Treatment Sales Value
6.3 United States
6.3.1 United States Indolent Lymphoma Treatment Sales Value, 2019-2030
6.3.2 United States Indolent Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Indolent Lymphoma Treatment Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Indolent Lymphoma Treatment Sales Value, 2019-2030
6.4.2 Europe Indolent Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Indolent Lymphoma Treatment Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Indolent Lymphoma Treatment Sales Value, 2019-2030
6.5.2 China Indolent Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
6.5.3 China Indolent Lymphoma Treatment Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Indolent Lymphoma Treatment Sales Value, 2019-2030
6.6.2 Japan Indolent Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Indolent Lymphoma Treatment Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Indolent Lymphoma Treatment Sales Value, 2019-2030
6.7.2 South Korea Indolent Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Indolent Lymphoma Treatment Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Indolent Lymphoma Treatment Sales Value, 2019-2030
6.8.2 Southeast Asia Indolent Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Indolent Lymphoma Treatment Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Indolent Lymphoma Treatment Sales Value, 2019-2030
6.9.2 India Indolent Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
6.9.3 India Indolent Lymphoma Treatment Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Altor BioScience Corporation
7.1.1 Altor BioScience Corporation Profile
7.1.2 Altor BioScience Corporation Main Business
7.1.3 Altor BioScience Corporation Indolent Lymphoma Treatment Products, Services and Solutions
7.1.4 Altor BioScience Corporation Indolent Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.1.5 Altor BioScience Corporation Recent Developments
7.2 Amgen Inc.
7.2.1 Amgen Inc. Profile
7.2.2 Amgen Inc. Main Business
7.2.3 Amgen Inc. Indolent Lymphoma Treatment Products, Services and Solutions
7.2.4 Amgen Inc. Indolent Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.2.5 Amgen Inc. Recent Developments
7.3 Astellas Pharma Inc.
7.3.1 Astellas Pharma Inc. Profile
7.3.2 Astellas Pharma Inc. Main Business
7.3.3 Astellas Pharma Inc. Indolent Lymphoma Treatment Products, Services and Solutions
7.3.4 Astellas Pharma Inc. Indolent Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.3.5 Bayer AG Recent Developments
7.4 Bayer AG
7.4.1 Bayer AG Profile
7.4.2 Bayer AG Main Business
7.4.3 Bayer AG Indolent Lymphoma Treatment Products, Services and Solutions
7.4.4 Bayer AG Indolent Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.4.5 Bayer AG Recent Developments
7.5 Boehringer Ingelheim GmbH
7.5.1 Boehringer Ingelheim GmbH Profile
7.5.2 Boehringer Ingelheim GmbH Main Business
7.5.3 Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Products, Services and Solutions
7.5.4 Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.5.5 Boehringer Ingelheim GmbH Recent Developments
7.6 Bristol-Myers Squibb Company
7.6.1 Bristol-Myers Squibb Company Profile
7.6.2 Bristol-Myers Squibb Company Main Business
7.6.3 Bristol-Myers Squibb Company Indolent Lymphoma Treatment Products, Services and Solutions
7.6.4 Bristol-Myers Squibb Company Indolent Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.6.5 Bristol-Myers Squibb Company Recent Developments
7.7 Celgene Corporation
7.7.1 Celgene Corporation Profile
7.7.2 Celgene Corporation Main Business
7.7.3 Celgene Corporation Indolent Lymphoma Treatment Products, Services and Solutions
7.7.4 Celgene Corporation Indolent Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.7.5 Celgene Corporation Recent Developments
7.8 Eli Lilly and Company
7.8.1 Eli Lilly and Company Profile
7.8.2 Eli Lilly and Company Main Business
7.8.3 Eli Lilly and Company Indolent Lymphoma Treatment Products, Services and Solutions
7.8.4 Eli Lilly and Company Indolent Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.8.5 Eli Lilly and Company Recent Developments
7.9 F. Hoffmann-La Roche Ltd.
7.9.1 F. Hoffmann-La Roche Ltd. Profile
7.9.2 F. Hoffmann-La Roche Ltd. Main Business
7.9.3 F. Hoffmann-La Roche Ltd. Indolent Lymphoma Treatment Products, Services and Solutions
7.9.4 F. Hoffmann-La Roche Ltd. Indolent Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.9.5 F. Hoffmann-La Roche Ltd. Recent Developments
7.10 Gilead Sciences, Inc.
7.10.1 Gilead Sciences, Inc. Profile
7.10.2 Gilead Sciences, Inc. Main Business
7.10.3 Gilead Sciences, Inc. Indolent Lymphoma Treatment Products, Services and Solutions
7.10.4 Gilead Sciences, Inc. Indolent Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.10.5 Gilead Sciences, Inc. Recent Developments
7.11 Incyte Corporation
7.11.1 Incyte Corporation Profile
7.11.2 Incyte Corporation Main Business
7.11.3 Incyte Corporation Indolent Lymphoma Treatment Products, Services and Solutions
7.11.4 Incyte Corporation Indolent Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.11.5 Incyte Corporation Recent Developments
7.12 Infinity Pharmaceuticals, Inc.
7.12.1 Infinity Pharmaceuticals, Inc. Profile
7.12.2 Infinity Pharmaceuticals, Inc. Main Business
7.12.3 Infinity Pharmaceuticals, Inc. Indolent Lymphoma Treatment Products, Services and Solutions
7.12.4 Infinity Pharmaceuticals, Inc. Indolent Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.12.5 Infinity Pharmaceuticals, Inc. Recent Developments
7.13 Juno Therapeutics Inc.
7.13.1 Juno Therapeutics Inc. Profile
7.13.2 Juno Therapeutics Inc. Main Business
7.13.3 Juno Therapeutics Inc. Indolent Lymphoma Treatment Products, Services and Solutions
7.13.4 Juno Therapeutics Inc. Indolent Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.13.5 Juno Therapeutics Inc. Recent Developments
7.14 MedImmune, LLC
7.14.1 MedImmune, LLC Profile
7.14.2 MedImmune, LLC Main Business
7.14.3 MedImmune, LLC Indolent Lymphoma Treatment Products, Services and Solutions
7.14.4 MedImmune, LLC Indolent Lymphoma Treatment Revenue (US$ Million) & (2019-2024)
7.14.5 MedImmune, LLC Recent Developments
8 Industry Chain Analysis
8.1 Indolent Lymphoma Treatment Industrial Chain
8.2 Indolent Lymphoma Treatment Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Indolent Lymphoma Treatment Sales Model
8.5.2 Sales Channel
8.5.3 Indolent Lymphoma Treatment Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Indolent Lymphoma Treatment Market Trends
Table 2. Indolent Lymphoma Treatment Market Drivers & Opportunity
Table 3. Indolent Lymphoma Treatment Market Challenges
Table 4. Indolent Lymphoma Treatment Market Restraints
Table 5. Global Indolent Lymphoma Treatment Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Indolent Lymphoma Treatment Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Indolent Lymphoma Treatment Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Indolent Lymphoma Treatment Product Type
Table 9. Key Companies Time to Begin Mass Production of Indolent Lymphoma Treatment
Table 10. Global Indolent Lymphoma Treatment Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Indolent Lymphoma Treatment as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Indolent Lymphoma Treatment Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Indolent Lymphoma Treatment Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Indolent Lymphoma Treatment Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Indolent Lymphoma Treatment Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Indolent Lymphoma Treatment Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Indolent Lymphoma Treatment Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Indolent Lymphoma Treatment Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Indolent Lymphoma Treatment Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Indolent Lymphoma Treatment Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Indolent Lymphoma Treatment Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Indolent Lymphoma Treatment Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Indolent Lymphoma Treatment Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Indolent Lymphoma Treatment Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Indolent Lymphoma Treatment Sales Value by Region (2019-2024) & (%)
Table 27. Global Indolent Lymphoma Treatment Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Indolent Lymphoma Treatment Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Indolent Lymphoma Treatment Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Indolent Lymphoma Treatment Sales Value, (2025-2030) & (US$ Million)
Table 31. Altor BioScience Corporation Basic Information List
Table 32. Altor BioScience Corporation Description and Business Overview
Table 33. Altor BioScience Corporation Indolent Lymphoma Treatment Products, Services and Solutions
Table 34. Revenue (US$ Million) in Indolent Lymphoma Treatment Business of Altor BioScience Corporation (2019-2024)
Table 35. Altor BioScience Corporation Recent Developments
Table 36. Amgen Inc. Basic Information List
Table 37. Amgen Inc. Description and Business Overview
Table 38. Amgen Inc. Indolent Lymphoma Treatment Products, Services and Solutions
Table 39. Revenue (US$ Million) in Indolent Lymphoma Treatment Business of Amgen Inc. (2019-2024)
Table 40. Amgen Inc. Recent Developments
Table 41. Astellas Pharma Inc. Basic Information List
Table 42. Astellas Pharma Inc. Description and Business Overview
Table 43. Astellas Pharma Inc. Indolent Lymphoma Treatment Products, Services and Solutions
Table 44. Revenue (US$ Million) in Indolent Lymphoma Treatment Business of Astellas Pharma Inc. (2019-2024)
Table 45. Astellas Pharma Inc. Recent Developments
Table 46. Bayer AG Basic Information List
Table 47. Bayer AG Description and Business Overview
Table 48. Bayer AG Indolent Lymphoma Treatment Products, Services and Solutions
Table 49. Revenue (US$ Million) in Indolent Lymphoma Treatment Business of Bayer AG (2019-2024)
Table 50. Bayer AG Recent Developments
Table 51. Boehringer Ingelheim GmbH Basic Information List
Table 52. Boehringer Ingelheim GmbH Description and Business Overview
Table 53. Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Products, Services and Solutions
Table 54. Revenue (US$ Million) in Indolent Lymphoma Treatment Business of Boehringer Ingelheim GmbH (2019-2024)
Table 55. Boehringer Ingelheim GmbH Recent Developments
Table 56. Bristol-Myers Squibb Company Basic Information List
Table 57. Bristol-Myers Squibb Company Description and Business Overview
Table 58. Bristol-Myers Squibb Company Indolent Lymphoma Treatment Products, Services and Solutions
Table 59. Revenue (US$ Million) in Indolent Lymphoma Treatment Business of Bristol-Myers Squibb Company (2019-2024)
Table 60. Bristol-Myers Squibb Company Recent Developments
Table 61. Celgene Corporation Basic Information List
Table 62. Celgene Corporation Description and Business Overview
Table 63. Celgene Corporation Indolent Lymphoma Treatment Products, Services and Solutions
Table 64. Revenue (US$ Million) in Indolent Lymphoma Treatment Business of Celgene Corporation (2019-2024)
Table 65. Celgene Corporation Recent Developments
Table 66. Eli Lilly and Company Basic Information List
Table 67. Eli Lilly and Company Description and Business Overview
Table 68. Eli Lilly and Company Indolent Lymphoma Treatment Products, Services and Solutions
Table 69. Revenue (US$ Million) in Indolent Lymphoma Treatment Business of Eli Lilly and Company (2019-2024)
Table 70. Eli Lilly and Company Recent Developments
Table 71. F. Hoffmann-La Roche Ltd. Basic Information List
Table 72. F. Hoffmann-La Roche Ltd. Description and Business Overview
Table 73. F. Hoffmann-La Roche Ltd. Indolent Lymphoma Treatment Products, Services and Solutions
Table 74. Revenue (US$ Million) in Indolent Lymphoma Treatment Business of F. Hoffmann-La Roche Ltd. (2019-2024)
Table 75. F. Hoffmann-La Roche Ltd. Recent Developments
Table 76. Gilead Sciences, Inc. Basic Information List
Table 77. Gilead Sciences, Inc. Description and Business Overview
Table 78. Gilead Sciences, Inc. Indolent Lymphoma Treatment Products, Services and Solutions
Table 79. Revenue (US$ Million) in Indolent Lymphoma Treatment Business of Gilead Sciences, Inc. (2019-2024)
Table 80. Gilead Sciences, Inc. Recent Developments
Table 81. Incyte Corporation Basic Information List
Table 82. Incyte Corporation Description and Business Overview
Table 83. Incyte Corporation Indolent Lymphoma Treatment Products, Services and Solutions
Table 84. Revenue (US$ Million) in Indolent Lymphoma Treatment Business of Incyte Corporation (2019-2024)
Table 85. Incyte Corporation Recent Developments
Table 86. Infinity Pharmaceuticals, Inc. Basic Information List
Table 87. Infinity Pharmaceuticals, Inc. Description and Business Overview
Table 88. Infinity Pharmaceuticals, Inc. Indolent Lymphoma Treatment Products, Services and Solutions
Table 89. Revenue (US$ Million) in Indolent Lymphoma Treatment Business of Infinity Pharmaceuticals, Inc. (2019-2024)
Table 90. Infinity Pharmaceuticals, Inc. Recent Developments
Table 91. Juno Therapeutics Inc. Basic Information List
Table 92. Juno Therapeutics Inc. Description and Business Overview
Table 93. Juno Therapeutics Inc. Indolent Lymphoma Treatment Products, Services and Solutions
Table 94. Revenue (US$ Million) in Indolent Lymphoma Treatment Business of Juno Therapeutics Inc. (2019-2024)
Table 95. Juno Therapeutics Inc. Recent Developments
Table 96. MedImmune, LLC Basic Information List
Table 97. MedImmune, LLC Description and Business Overview
Table 98. MedImmune, LLC Indolent Lymphoma Treatment Products, Services and Solutions
Table 99. Revenue (US$ Million) in Indolent Lymphoma Treatment Business of MedImmune, LLC (2019-2024)
Table 100. MedImmune, LLC Recent Developments
Table 101. Key Raw Materials Lists
Table 102. Raw Materials Key Suppliers Lists
Table 103. Indolent Lymphoma Treatment Downstream Customers
Table 104. Indolent Lymphoma Treatment Distributors List
Table 105. Research Programs/Design for This Report
Table 106. Key Data Information from Secondary Sources
Table 107. Key Data Information from Primary Sources
Table 108. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Indolent Lymphoma Treatment Product Picture
Figure 2. Global Indolent Lymphoma Treatment Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Indolent Lymphoma Treatment Sales Value (2019-2030) & (US$ Million)
Figure 4. Indolent Lymphoma Treatment Report Years Considered
Figure 5. Global Indolent Lymphoma Treatment Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Indolent Lymphoma Treatment Revenue in 2023
Figure 7. Indolent Lymphoma Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. BI-836826 Picture
Figure 9. ALT-803 Picture
Figure 10. BMS-986016 Picture
Figure 11. CC-122 Picture
Figure 12. Others Picture
Figure 13. Global Indolent Lymphoma Treatment Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 14. Global Indolent Lymphoma Treatment Sales Value Market Share by Type, 2023 & 2030
Figure 15. Product Picture of Hospital
Figure 16. Product Picture of Clinic
Figure 17. Product Picture of Others
Figure 18. Global Indolent Lymphoma Treatment Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 19. Global Indolent Lymphoma Treatment Sales Value Market Share by Application, 2023 & 2030
Figure 20. North America Indolent Lymphoma Treatment Sales Value (2019-2030) & (US$ Million)
Figure 21. North America Indolent Lymphoma Treatment Sales Value by Country (%), 2023 VS 2030
Figure 22. Europe Indolent Lymphoma Treatment Sales Value (2019-2030) & (US$ Million)
Figure 23. Europe Indolent Lymphoma Treatment Sales Value by Country (%), 2023 VS 2030
Figure 24. Asia Pacific Indolent Lymphoma Treatment Sales Value (2019-2030) & (US$ Million)
Figure 25. Asia Pacific Indolent Lymphoma Treatment Sales Value by Country (%), 2023 VS 2030
Figure 26. South America Indolent Lymphoma Treatment Sales Value (2019-2030) & (US$ Million)
Figure 27. South America Indolent Lymphoma Treatment Sales Value by Country (%), 2023 VS 2030
Figure 28. Middle East & Africa Indolent Lymphoma Treatment Sales Value (2019-2030) & (US$ Million)
Figure 29. Middle East & Africa Indolent Lymphoma Treatment Sales Value by Country (%), 2023 VS 2030
Figure 30. Key Countries/Regions Indolent Lymphoma Treatment Sales Value (%), (2019-2030)
Figure 31. United States Indolent Lymphoma Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 32. United States Indolent Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
Figure 33. United States Indolent Lymphoma Treatment Sales Value by Application (%), 2023 VS 2030
Figure 34. Europe Indolent Lymphoma Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 35. Europe Indolent Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
Figure 36. Europe Indolent Lymphoma Treatment Sales Value by Application (%), 2023 VS 2030
Figure 37. China Indolent Lymphoma Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 38. China Indolent Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
Figure 39. China Indolent Lymphoma Treatment Sales Value by Application (%), 2023 VS 2030
Figure 40. Japan Indolent Lymphoma Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 41. Japan Indolent Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
Figure 42. Japan Indolent Lymphoma Treatment Sales Value by Application (%), 2023 VS 2030
Figure 43. South Korea Indolent Lymphoma Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 44. South Korea Indolent Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
Figure 45. South Korea Indolent Lymphoma Treatment Sales Value by Application (%), 2023 VS 2030
Figure 46. Southeast Asia Indolent Lymphoma Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 47. Southeast Asia Indolent Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
Figure 48. Southeast Asia Indolent Lymphoma Treatment Sales Value by Application (%), 2023 VS 2030
Figure 49. India Indolent Lymphoma Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 50. India Indolent Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
Figure 51. India Indolent Lymphoma Treatment Sales Value by Application (%), 2023 VS 2030
Figure 52. Indolent Lymphoma Treatment Industrial Chain
Figure 53. Indolent Lymphoma Treatment Manufacturing Cost Structure
Figure 54. Channels of Distribution (Direct Sales, and Distribution)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Table 1. Indolent Lymphoma Treatment Market Trends
Table 2. Indolent Lymphoma Treatment Market Drivers & Opportunity
Table 3. Indolent Lymphoma Treatment Market Challenges
Table 4. Indolent Lymphoma Treatment Market Restraints
Table 5. Global Indolent Lymphoma Treatment Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Indolent Lymphoma Treatment Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Indolent Lymphoma Treatment Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Indolent Lymphoma Treatment Product Type
Table 9. Key Companies Time to Begin Mass Production of Indolent Lymphoma Treatment
Table 10. Global Indolent Lymphoma Treatment Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Indolent Lymphoma Treatment as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Indolent Lymphoma Treatment Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Indolent Lymphoma Treatment Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Indolent Lymphoma Treatment Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Indolent Lymphoma Treatment Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Indolent Lymphoma Treatment Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Indolent Lymphoma Treatment Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Indolent Lymphoma Treatment Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Indolent Lymphoma Treatment Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Indolent Lymphoma Treatment Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Indolent Lymphoma Treatment Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Indolent Lymphoma Treatment Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Indolent Lymphoma Treatment Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Indolent Lymphoma Treatment Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Indolent Lymphoma Treatment Sales Value by Region (2019-2024) & (%)
Table 27. Global Indolent Lymphoma Treatment Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Indolent Lymphoma Treatment Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Indolent Lymphoma Treatment Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Indolent Lymphoma Treatment Sales Value, (2025-2030) & (US$ Million)
Table 31. Altor BioScience Corporation Basic Information List
Table 32. Altor BioScience Corporation Description and Business Overview
Table 33. Altor BioScience Corporation Indolent Lymphoma Treatment Products, Services and Solutions
Table 34. Revenue (US$ Million) in Indolent Lymphoma Treatment Business of Altor BioScience Corporation (2019-2024)
Table 35. Altor BioScience Corporation Recent Developments
Table 36. Amgen Inc. Basic Information List
Table 37. Amgen Inc. Description and Business Overview
Table 38. Amgen Inc. Indolent Lymphoma Treatment Products, Services and Solutions
Table 39. Revenue (US$ Million) in Indolent Lymphoma Treatment Business of Amgen Inc. (2019-2024)
Table 40. Amgen Inc. Recent Developments
Table 41. Astellas Pharma Inc. Basic Information List
Table 42. Astellas Pharma Inc. Description and Business Overview
Table 43. Astellas Pharma Inc. Indolent Lymphoma Treatment Products, Services and Solutions
Table 44. Revenue (US$ Million) in Indolent Lymphoma Treatment Business of Astellas Pharma Inc. (2019-2024)
Table 45. Astellas Pharma Inc. Recent Developments
Table 46. Bayer AG Basic Information List
Table 47. Bayer AG Description and Business Overview
Table 48. Bayer AG Indolent Lymphoma Treatment Products, Services and Solutions
Table 49. Revenue (US$ Million) in Indolent Lymphoma Treatment Business of Bayer AG (2019-2024)
Table 50. Bayer AG Recent Developments
Table 51. Boehringer Ingelheim GmbH Basic Information List
Table 52. Boehringer Ingelheim GmbH Description and Business Overview
Table 53. Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Products, Services and Solutions
Table 54. Revenue (US$ Million) in Indolent Lymphoma Treatment Business of Boehringer Ingelheim GmbH (2019-2024)
Table 55. Boehringer Ingelheim GmbH Recent Developments
Table 56. Bristol-Myers Squibb Company Basic Information List
Table 57. Bristol-Myers Squibb Company Description and Business Overview
Table 58. Bristol-Myers Squibb Company Indolent Lymphoma Treatment Products, Services and Solutions
Table 59. Revenue (US$ Million) in Indolent Lymphoma Treatment Business of Bristol-Myers Squibb Company (2019-2024)
Table 60. Bristol-Myers Squibb Company Recent Developments
Table 61. Celgene Corporation Basic Information List
Table 62. Celgene Corporation Description and Business Overview
Table 63. Celgene Corporation Indolent Lymphoma Treatment Products, Services and Solutions
Table 64. Revenue (US$ Million) in Indolent Lymphoma Treatment Business of Celgene Corporation (2019-2024)
Table 65. Celgene Corporation Recent Developments
Table 66. Eli Lilly and Company Basic Information List
Table 67. Eli Lilly and Company Description and Business Overview
Table 68. Eli Lilly and Company Indolent Lymphoma Treatment Products, Services and Solutions
Table 69. Revenue (US$ Million) in Indolent Lymphoma Treatment Business of Eli Lilly and Company (2019-2024)
Table 70. Eli Lilly and Company Recent Developments
Table 71. F. Hoffmann-La Roche Ltd. Basic Information List
Table 72. F. Hoffmann-La Roche Ltd. Description and Business Overview
Table 73. F. Hoffmann-La Roche Ltd. Indolent Lymphoma Treatment Products, Services and Solutions
Table 74. Revenue (US$ Million) in Indolent Lymphoma Treatment Business of F. Hoffmann-La Roche Ltd. (2019-2024)
Table 75. F. Hoffmann-La Roche Ltd. Recent Developments
Table 76. Gilead Sciences, Inc. Basic Information List
Table 77. Gilead Sciences, Inc. Description and Business Overview
Table 78. Gilead Sciences, Inc. Indolent Lymphoma Treatment Products, Services and Solutions
Table 79. Revenue (US$ Million) in Indolent Lymphoma Treatment Business of Gilead Sciences, Inc. (2019-2024)
Table 80. Gilead Sciences, Inc. Recent Developments
Table 81. Incyte Corporation Basic Information List
Table 82. Incyte Corporation Description and Business Overview
Table 83. Incyte Corporation Indolent Lymphoma Treatment Products, Services and Solutions
Table 84. Revenue (US$ Million) in Indolent Lymphoma Treatment Business of Incyte Corporation (2019-2024)
Table 85. Incyte Corporation Recent Developments
Table 86. Infinity Pharmaceuticals, Inc. Basic Information List
Table 87. Infinity Pharmaceuticals, Inc. Description and Business Overview
Table 88. Infinity Pharmaceuticals, Inc. Indolent Lymphoma Treatment Products, Services and Solutions
Table 89. Revenue (US$ Million) in Indolent Lymphoma Treatment Business of Infinity Pharmaceuticals, Inc. (2019-2024)
Table 90. Infinity Pharmaceuticals, Inc. Recent Developments
Table 91. Juno Therapeutics Inc. Basic Information List
Table 92. Juno Therapeutics Inc. Description and Business Overview
Table 93. Juno Therapeutics Inc. Indolent Lymphoma Treatment Products, Services and Solutions
Table 94. Revenue (US$ Million) in Indolent Lymphoma Treatment Business of Juno Therapeutics Inc. (2019-2024)
Table 95. Juno Therapeutics Inc. Recent Developments
Table 96. MedImmune, LLC Basic Information List
Table 97. MedImmune, LLC Description and Business Overview
Table 98. MedImmune, LLC Indolent Lymphoma Treatment Products, Services and Solutions
Table 99. Revenue (US$ Million) in Indolent Lymphoma Treatment Business of MedImmune, LLC (2019-2024)
Table 100. MedImmune, LLC Recent Developments
Table 101. Key Raw Materials Lists
Table 102. Raw Materials Key Suppliers Lists
Table 103. Indolent Lymphoma Treatment Downstream Customers
Table 104. Indolent Lymphoma Treatment Distributors List
Table 105. Research Programs/Design for This Report
Table 106. Key Data Information from Secondary Sources
Table 107. Key Data Information from Primary Sources
Table 108. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Indolent Lymphoma Treatment Product Picture
Figure 2. Global Indolent Lymphoma Treatment Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Indolent Lymphoma Treatment Sales Value (2019-2030) & (US$ Million)
Figure 4. Indolent Lymphoma Treatment Report Years Considered
Figure 5. Global Indolent Lymphoma Treatment Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Indolent Lymphoma Treatment Revenue in 2023
Figure 7. Indolent Lymphoma Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. BI-836826 Picture
Figure 9. ALT-803 Picture
Figure 10. BMS-986016 Picture
Figure 11. CC-122 Picture
Figure 12. Others Picture
Figure 13. Global Indolent Lymphoma Treatment Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 14. Global Indolent Lymphoma Treatment Sales Value Market Share by Type, 2023 & 2030
Figure 15. Product Picture of Hospital
Figure 16. Product Picture of Clinic
Figure 17. Product Picture of Others
Figure 18. Global Indolent Lymphoma Treatment Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 19. Global Indolent Lymphoma Treatment Sales Value Market Share by Application, 2023 & 2030
Figure 20. North America Indolent Lymphoma Treatment Sales Value (2019-2030) & (US$ Million)
Figure 21. North America Indolent Lymphoma Treatment Sales Value by Country (%), 2023 VS 2030
Figure 22. Europe Indolent Lymphoma Treatment Sales Value (2019-2030) & (US$ Million)
Figure 23. Europe Indolent Lymphoma Treatment Sales Value by Country (%), 2023 VS 2030
Figure 24. Asia Pacific Indolent Lymphoma Treatment Sales Value (2019-2030) & (US$ Million)
Figure 25. Asia Pacific Indolent Lymphoma Treatment Sales Value by Country (%), 2023 VS 2030
Figure 26. South America Indolent Lymphoma Treatment Sales Value (2019-2030) & (US$ Million)
Figure 27. South America Indolent Lymphoma Treatment Sales Value by Country (%), 2023 VS 2030
Figure 28. Middle East & Africa Indolent Lymphoma Treatment Sales Value (2019-2030) & (US$ Million)
Figure 29. Middle East & Africa Indolent Lymphoma Treatment Sales Value by Country (%), 2023 VS 2030
Figure 30. Key Countries/Regions Indolent Lymphoma Treatment Sales Value (%), (2019-2030)
Figure 31. United States Indolent Lymphoma Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 32. United States Indolent Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
Figure 33. United States Indolent Lymphoma Treatment Sales Value by Application (%), 2023 VS 2030
Figure 34. Europe Indolent Lymphoma Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 35. Europe Indolent Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
Figure 36. Europe Indolent Lymphoma Treatment Sales Value by Application (%), 2023 VS 2030
Figure 37. China Indolent Lymphoma Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 38. China Indolent Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
Figure 39. China Indolent Lymphoma Treatment Sales Value by Application (%), 2023 VS 2030
Figure 40. Japan Indolent Lymphoma Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 41. Japan Indolent Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
Figure 42. Japan Indolent Lymphoma Treatment Sales Value by Application (%), 2023 VS 2030
Figure 43. South Korea Indolent Lymphoma Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 44. South Korea Indolent Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
Figure 45. South Korea Indolent Lymphoma Treatment Sales Value by Application (%), 2023 VS 2030
Figure 46. Southeast Asia Indolent Lymphoma Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 47. Southeast Asia Indolent Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
Figure 48. Southeast Asia Indolent Lymphoma Treatment Sales Value by Application (%), 2023 VS 2030
Figure 49. India Indolent Lymphoma Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 50. India Indolent Lymphoma Treatment Sales Value by Type (%), 2023 VS 2030
Figure 51. India Indolent Lymphoma Treatment Sales Value by Application (%), 2023 VS 2030
Figure 52. Indolent Lymphoma Treatment Industrial Chain
Figure 53. Indolent Lymphoma Treatment Manufacturing Cost Structure
Figure 54. Channels of Distribution (Direct Sales, and Distribution)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
DigitalBroadcast and Cinematography Cameras Lease - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Mobile and Web Event Analytics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Business Information - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232